Literature DB >> 11979328

Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1.

M Nakane1, G Hsieh, L N Miller, R Chang, M A Terranova, R B Moreland, T Kolasa, J D Brioni.   

Abstract

Nitric oxide (NO) activates corpus cavernosum smooth muscle soluble guanylate cyclase (sGC) and increases the synthesis of cGMP that results in smooth muscle relaxation and ultimately, penile erection. To characterize sGC and define the potential synergy between NO and the allosteric activator YC-1 in corpus cavernosum, rat sGC was activated by either sodium nitroprusside (SNP) or YC-1, and YC-1 potentiated the effects of SNP with a 200-fold activation of sGC. Both SNP and YC-1 decreased the Km and increased the Vmax. ODQ significantly inhibited sGC activated by SNP with IC50 of 0.5 nM, but did not affect the sGC activated by YC-1 as well as basal sGC activity. SNP and YC-1 synergistically increased intracellular cGMP levels in rabbit corpus cavernosum smooth muscle cell cultures. YC-1 significantly relaxed rabbit cavernosum tissue strips in organ baths with an EC50 of 8.4 microM. In the presence of L-nitroarginine methyl ester to block endogenous NO production, co-administration of SNP shifted the dose response of YC-1 to the left, showing the synergism of SNP and YC-1 in tissue strips. In view of the clinical efficacy of phosphodiesterase-5 inhibitors, activation of sGC may provide an alternative means for enhancing the activity of neurally derived NO during sexual stimulation in the corpus cavernosum, representing a novel approach for the treatment of erectile dysfunction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11979328     DOI: 10.1038/sj.ijir.3900843

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  15 in total

Review 1.  Therapy of erectile dysfunction: potential future treatments.

Authors:  Nestor F Gonzalez-Cadavid; Jacob Rajfer
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.633

Review 2.  [Therapy for organic erectile dysfunction].

Authors:  A J Becker; M Mayer; C G Stief
Journal:  Urologe A       Date:  2005-10       Impact factor: 0.639

Review 3.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Authors:  Oleg V Evgenov; Pál Pacher; Peter M Schmidt; György Haskó; Harald H H W Schmidt; Johannes-Peter Stasch
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

Review 4.  In vitro models: research in physiology and pharmacology of the lower urinary tract.

Authors:  Robert B Moreland
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

5.  In vitro and in vivo studies on the importance of the soluble guanylyl cyclase α1 subunit in penile erection.

Authors:  Kelly Decaluwé; Sofie Nimmegeers; Robrecht Thoonen; Emanuel Buys; Peter Brouckaert; Johan Van de Voorde
Journal:  World J Urol       Date:  2010-01-23       Impact factor: 4.226

6.  A Review of the Pathophysiology and Novel Treatments for Erectile Dysfunction.

Authors:  George F Lasker; Jason H Maley; Philip J Kadowitz
Journal:  Adv Pharmacol Sci       Date:  2010

7.  [Therapy of erectile dysfunction in 2005].

Authors:  H Porst
Journal:  Urologe A       Date:  2003-10       Impact factor: 0.639

8.  A constitutively activated mutant of human soluble guanylyl cyclase (sGC): implication for the mechanism of sGC activation.

Authors:  Emil Martin; Iraida Sharina; Alexander Kots; Ferid Murad
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-25       Impact factor: 11.205

9.  Inhibition of soluble guanylyl cyclase by small molecules targeting the catalytic domain.

Authors:  Jagamya Vijayaraghavan; Kristopher Kramp; Michael E Harris; Focco van den Akker
Journal:  FEBS Lett       Date:  2016-10-04       Impact factor: 4.124

10.  Analysis of erectile responses to BAY 41-8543 and muscarinic receptor stimulation in the rat.

Authors:  George F Lasker; Edward A Pankey; Alexander V Allain; Jasdeep S Dhaliwal; Johannes-Peter Stasch; Subramanyam N Murthy; Philip J Kadowitz
Journal:  J Sex Med       Date:  2012-09-18       Impact factor: 3.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.